JP2024538721A - Gabaa受容体活性を有するフラボノイド誘導体および使用方法 - Google Patents
Gabaa受容体活性を有するフラボノイド誘導体および使用方法 Download PDFInfo
- Publication number
- JP2024538721A JP2024538721A JP2024521052A JP2024521052A JP2024538721A JP 2024538721 A JP2024538721 A JP 2024538721A JP 2024521052 A JP2024521052 A JP 2024521052A JP 2024521052 A JP2024521052 A JP 2024521052A JP 2024538721 A JP2024538721 A JP 2024538721A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- bond
- group
- occurrence
- groups
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
- C07D265/22—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163253341P | 2021-10-07 | 2021-10-07 | |
| US63/253,341 | 2021-10-07 | ||
| PCT/US2022/045904 WO2023059802A1 (en) | 2021-10-07 | 2022-10-06 | Flavonoid derivatives with gabaa receptor activity and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538721A true JP2024538721A (ja) | 2024-10-23 |
| JP2024538721A5 JP2024538721A5 (cg-RX-API-DMAC7.html) | 2025-09-30 |
Family
ID=85803715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521052A Pending JP2024538721A (ja) | 2021-10-07 | 2022-10-06 | Gabaa受容体活性を有するフラボノイド誘導体および使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240398821A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4412605A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538721A (cg-RX-API-DMAC7.html) |
| CN (1) | CN118354770A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022361421A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3233822A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023059802A1 (cg-RX-API-DMAC7.html) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5251378A (en) * | 1975-10-20 | 1977-04-25 | Chugai Pharmaceut Co Ltd | Preparation of 4(3h)-quinazolinone derivatives |
| JPH07506386A (ja) * | 1992-04-27 | 1995-07-13 | フロリダ・ステート・ユニバーシティー | 低自己吸収性の固有にシンチレートするポリマー |
| JP2000505055A (ja) * | 1995-10-17 | 2000-04-25 | ユニバーシティ オブ ストラスクライド | 不安の治療に対するニトロフラボノイドの使用 |
| WO2001083456A1 (en) * | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| JP2002504481A (ja) * | 1998-02-18 | 2002-02-12 | ニューロサーチ、アクティーゼルスカブ | 新規化合物及び陽性ampaレセプターモジュレーターとしてこれを使用する方法 |
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| JP2013536238A (ja) * | 2010-08-24 | 2013-09-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法 |
| CN106478525A (zh) * | 2015-08-28 | 2017-03-08 | 南京理工大学 | 一种合成喹唑酮的方法 |
| CN109879820A (zh) * | 2019-02-26 | 2019-06-14 | 扬州大学 | 一种喹唑啉酮杂环化合物的合成方法 |
-
2022
- 2022-10-06 CN CN202280080629.4A patent/CN118354770A/zh active Pending
- 2022-10-06 JP JP2024521052A patent/JP2024538721A/ja active Pending
- 2022-10-06 AU AU2022361421A patent/AU2022361421A1/en active Pending
- 2022-10-06 CA CA3233822A patent/CA3233822A1/en active Pending
- 2022-10-06 WO PCT/US2022/045904 patent/WO2023059802A1/en not_active Ceased
- 2022-10-06 EP EP22879291.7A patent/EP4412605A4/en active Pending
- 2022-10-06 US US18/699,103 patent/US20240398821A1/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5251378A (en) * | 1975-10-20 | 1977-04-25 | Chugai Pharmaceut Co Ltd | Preparation of 4(3h)-quinazolinone derivatives |
| JPH07506386A (ja) * | 1992-04-27 | 1995-07-13 | フロリダ・ステート・ユニバーシティー | 低自己吸収性の固有にシンチレートするポリマー |
| JP2000505055A (ja) * | 1995-10-17 | 2000-04-25 | ユニバーシティ オブ ストラスクライド | 不安の治療に対するニトロフラボノイドの使用 |
| JP2002504481A (ja) * | 1998-02-18 | 2002-02-12 | ニューロサーチ、アクティーゼルスカブ | 新規化合物及び陽性ampaレセプターモジュレーターとしてこれを使用する方法 |
| WO2001083456A1 (en) * | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Condensed heteroaryl derivatives |
| WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| JP2013536238A (ja) * | 2010-08-24 | 2013-09-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジヒドロミリセチンの投与を含む、アルコール中毒、アルコール使用障害およびアルコール乱用の治療方法 |
| CN106478525A (zh) * | 2015-08-28 | 2017-03-08 | 南京理工大学 | 一种合成喹唑酮的方法 |
| CN109879820A (zh) * | 2019-02-26 | 2019-06-14 | 扬州大学 | 一种喹唑啉酮杂环化合物的合成方法 |
Non-Patent Citations (10)
| Title |
|---|
| ELISA OGNIBENE, ET AL.: "Behavioral effects of 6-bromoflavanone and 5-methoxy-6,8-dibromoflavanone as anxiolytic compounds", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, vol. 32(1), JPN7026003368, 2008, pages 128 - 134, ISSN: 0005920291 * |
| GYORGY LITKEI, ET AL.: "Hydroxymethylation of flavanones", ORG. PREP. PROC. INT., vol. 23(6), JPN7026003366, 1991, pages 741 - 747, ISSN: 0005920289 * |
| HARRY L. YALE AND MARION KALKSTEIN: "Substituted 2,3-Dihydro-4(1H)-quinazolinones. A New Class of Inhibitors of Cell Multiplication", J. MED. CHEM, vol. 10(2), JPN7026003373, 1967, pages 334 - 336, ISSN: 0005920296 * |
| LIHUAN REN, ET AL.: "Effects of flavone 6-substitutions on GABAA receptors efficacy", ERU. J. PHARM., vol. 670(1), JPN7026003370, 2011, pages 121 - 129, ISSN: 0005920293 * |
| MARIEL MARDER, ET AL.: "Molecular modeling and QSAR analysis of the interaction of flavone derivatives with the benzodiazepi", BIOORG. MED. CHEM., vol. 9(2), JPN7026003371, 2001, pages 323 - 335, ISSN: 0005920294 * |
| MICHAEL S.Y. HUEN, ET AL.: "Naturally occurring 20-hydroxyl-substituted flavonoids as high-affinitybenzodiazepine site ligands", BIOCHEM. PHARM., vol. 66(12), JPN7026003367, 2003, pages 2397 - 2407, ISSN: 0005920290 * |
| SHWETA MISHRA, ET AL.: "Electronegativity in Substituted-4(H)-quinazolinones Causes Anxiolysis without a Sedative-hypnotic A", CENTRAL NERVOUS SYSTEM AGENTS IN MEDICINAL CHEMISTRY, vol. 20(1), JPN7026003372, 2020, pages 26 - 40, ISSN: 0005920295 * |
| SOMEPALLI VENKATESWARLU, ET AL.: "Fused Quinazolinoquinazolinones: Synthesis, Isomerization, Spectroscopic Identification, and Antican", J.HETEROCYC.CHEM., vol. 52(6), JPN7026003374, 2015, pages 1631 - 1638, ISSN: 0005920297 * |
| WON-JEA CHO, ET AL.: "Synthesis and biological evaluation of 3-arylisoquinolines as antitumor agents", BIOORG. MED. CHEM., vol. 8(1), JPN7026003375, 1998, pages 41 - 46, ISSN: 0005920298 * |
| XIAOQIN HUANG, ET AL.: "3D-QSAR Model of Flavonoids Binding at Benzodiazepine Site in GABAAReceptors", J. MED. CHEM., vol. 44(12), JPN7026003369, 2001, pages 1883 - 1891, ISSN: 0005920292 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4412605A4 (en) | 2025-07-30 |
| CN118354770A (zh) | 2024-07-16 |
| CA3233822A1 (en) | 2023-04-13 |
| US20240398821A1 (en) | 2024-12-05 |
| EP4412605A1 (en) | 2024-08-14 |
| AU2022361421A1 (en) | 2024-05-09 |
| WO2023059802A1 (en) | 2023-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2449996C2 (ru) | СОЕДИНЕНИЯ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЗАИМОДЕЙСТВИЯ БЕЛКОВ Bcl С ПАРТНЕРАМИ СВЯЗЫВАНИЯ | |
| US20230365542A1 (en) | Selective Agonists of 5-HT2A Receptor and Methods of Use | |
| CN101006065B (zh) | 抑制bcl蛋白与结合伴侣的相互作用的化合物和方法 | |
| WO2024010585A1 (en) | Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use | |
| TW201940487A (zh) | sGC刺激劑之晶型 | |
| CN101374807B (zh) | 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法 | |
| US20240398821A1 (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| CN102046163A (zh) | 使用乌地那非(udenafil)与阿呋唑嗪(alfuzosin)或奥昔布宁(oxybutynin)组合治疗膀胱过度活动症 | |
| AU2003267557B2 (en) | Treatment of dyskinesia | |
| WO2022162193A1 (en) | Methods for the treatment of childhood-onset fluency disorder | |
| WO2025217596A1 (en) | Substituted 2,3-dihydro-4h-benzo[e][ 1,3] oxazin-4-one compounds and methods of use thereof | |
| HK40115276A (en) | Flavonoid derivatives with gabaa receptor activity and methods of use | |
| US20220388980A1 (en) | Quinoline inhibitors of rad52 and methods of use | |
| WO2025217249A1 (en) | Methods for treating endometriosis and/or other ovary-related diseases and for monitoring treatment | |
| JP2004300147A (ja) | 受容体拮抗剤 | |
| KR20250129797A (ko) | 글루코오스 수치를 조절하기 위한 조성물 및 방법 | |
| WO2021046789A1 (zh) | 吲唑-甲酰胺衍生物及其用途 | |
| EP1815854A1 (en) | Treatment of dyskenesia | |
| HK1105963B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| CA2991236A1 (en) | Therapeutic compounds and compositions for treating social disorders and substance use disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250919 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250919 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260626 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260715 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260730 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260807 |